Farobest200 mg

Farobest is an oral penem-class (beta-lactam) antibiotic used for the treatment of mild-to-moderate bacterial infections caused by susceptible organisms. It is marketed and used in several countries (including Bangladesh, India and Japan) for the indications below; it has not been approved by the US FDA and is not available in the United States.

• Established/guideline-supported uses:
  • Acute bacterial sinusitis
  • Community-acquired pneumonia and other lower respiratory tract infections (acute bronchitis, pulmonary suppuration) caused by susceptible strains
  • Pharyngitis and tonsillitis
  • Uncomplicated urinary tract infections (cystitis), pyelonephritis and prostatitis
  • Uncomplicated skin and skin-structure infections (folliculitis, impetigo, erysipelas, abscesses, pustular acne)
• Other reported uses (regional labeling, less robust evidence): otitis externa, tympanitis (middle ear infection), and gynecological infections such as adnexitis and Bartholin's gland inflammation.

Farobest should only be used for infections proven or strongly suspected to be caused by susceptible bacteria; it is not effective against viral infections.

Each tablet of Faropenem typically contains Faropenem (as faropenem sodium or faropenem medoxomil, depending on the manufacturer) as the active ingredient, commonly available in 150 mg and 200 mg strengths, along with standard pharmaceutical excipients.

Farobest is a synthetic oral penem antibiotic, structurally related to the carbapenem class of beta-lactam antibiotics. It has a broad spectrum of activity covering many aerobic and anaerobic Gram-positive and Gram-negative bacteria, and it retains activity against a number of organisms that produce beta-lactamase enzymes because it is relatively stable to hydrolysis by many of these enzymes.

Farobest is administered orally, which makes it useful as a step-down or outpatient option for infections that would otherwise require a parenteral beta-lactam.

Farobest belongs to the penem class of beta-lactam antibiotics, a group structurally related to both penicillins and carbapenems.

Faropenem is bactericidal. Like other beta-lactam antibiotics, it acts by binding to penicillin-binding proteins (PBPs) located in the bacterial cell wall, thereby inhibiting the final transpeptidation step of peptidoglycan synthesis. This weakens the bacterial cell wall, leading to cell lysis and death.

Faropenem has high affinity for several PBPs and demonstrates relative stability against many beta-lactamase enzymes, which broadens its activity against certain resistant organisms compared to older oral beta-lactams.

Farobest tablets are taken by mouth, generally with a full glass of water. It may be taken with or without food, although taking it with food may help reduce stomach upset. Doses should be spaced evenly through the day (e.g., every 8 hours for a three-times-daily regimen) and the full course should be completed even if symptoms improve early.

Farobest has the following clinically significant interactions:

• Valproic acid / sodium valproate: Beta-lactam antibiotics, including Farobest, can significantly reduce serum valproic acid concentrations, which may result in loss of seizure control. Concurrent use should be avoided where possible; if unavoidable, valproic acid levels and seizure control should be monitored closely.
• Probenecid: May reduce renal clearance of Farobest, increasing and prolonging its blood levels.
• Furosemide and other potentially nephrotoxic drugs: Concurrent use with Farobest may increase the risk of kidney toxicity; renal function should be monitored.
• Other beta-lactams (e.g., imipenem/cilastatin): Co-administration may alter blood concentrations of Farobest; such combinations should only be used under medical supervision.

Always inform your physician or pharmacist of all medicines, supplements, and herbal products being used before starting Farobest.

Farobest is generally well tolerated. Reported side effects include:

• Common: diarrhea, nausea, abdominal pain, vomiting, headache, and skin rash.
• Less common: dizziness, taste disturbance, elevated liver enzymes, and mild hypersensitivity reactions (itching, urticaria).
• Rare but serious: severe allergic/anaphylactic reactions, Clostridioides difficile-associated diarrhea (antibiotic-associated colitis), and seizures (more likely with high doses or in patients with renal impairment or seizure disorders — see Precautions and Warnings).

Patients should seek medical attention promptly if severe rash, difficulty breathing, swelling of the face/throat, or persistent severe diarrhea occurs while taking Farobest.

Pregnancy: Adequate and well-controlled studies of Farobest in pregnant women are lacking, and safety during pregnancy has not been established. Farobest should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; a physician should always be consulted before use.

Lactation: Farobest is known to pass into breast milk in small amounts. It should be used during breastfeeding only if the expected benefit outweighs the potential risk to the infant, and only under medical advice; the infant should be monitored for possible effects such as diarrhea or thrush.

Use Farobest with caution in the following situations:

• History of penicillin, cephalosporin, or carbapenem allergy: Partial cross-sensitivity is possible even without a documented anaphylactic reaction; use only with close monitoring.
• Seizure disorders: Beta-lactam antibiotics, including Farobest, may lower the seizure threshold, particularly at high doses or in patients with renal impairment; use with caution in patients with a history of seizures.
• Renal impairment: Dose adjustment may be required; see Dosage and Administration.
• Elderly patients and those with poor nutritional status: May be at higher risk of vitamin K deficiency-related bleeding with prolonged beta-lactam use; monitor accordingly.
• Prolonged use: May result in overgrowth of non-susceptible organisms, including Clostridioides difficile; discontinue and seek medical advice if severe or persistent diarrhea develops.

Antibiotic stewardship: Take Farobest exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

There is no specific antidote for Farobest overdose. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services. Management is supportive and symptomatic; since Farobest is eliminated renally, adequate hydration and monitoring of renal function are generally recommended, and hemodialysis may assist elimination in severe cases if clinically indicated.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric patients: Safety and efficacy of Farobest in children have not been well established; it is generally not recommended for use in children unless specifically directed by a pediatrician.
• Elderly patients: May require lower starting doses due to age-related decline in renal function; monitor for adverse effects, including vitamin K deficiency-related bleeding.
• Renal impairment: Dose reduction or extended dosing interval recommended; see Dosage and Administration.
• Hepatic impairment: No specific dose adjustment established; use with general caution.
• Pregnancy and lactation: See Pregnancy and Lactation section.

Duration of treatment with Farobest typically ranges from 5 to 10 days depending on the type and severity of infection and clinical response, as determined by the treating physician. Patients should complete the full prescribed course even if they start to feel better before it is finished, to reduce the risk of relapse and antibiotic resistance.

Faropenem is classified as an oral penem antibiotic, part of the broader beta-lactam antibiotic family that also includes penicillins, cephalosporins, and carbapenems.

Faropenem exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs) in the bacterial cell wall, inhibiting peptidoglycan cross-linking (the final step of cell wall synthesis). This disrupts cell wall integrity and leads to bacterial cell lysis and death. Faropenem also shows relative stability against many beta-lactamase enzymes, extending its activity against some resistant bacteria.

Safety and efficacy of Farobest in pediatric patients have not been well established through adequate controlled studies. As a result, Farobest is generally not recommended for routine use in children, and should only be used in pediatric patients if specifically prescribed by a physician who has judged the benefits to outweigh the uncertainties, with close monitoring for adverse effects.